7月14日,全球科学与技术的创新者丹纳赫在沪宣布其旗下运营公司Cytiva思拓凡与正序生物开展战略合作,共同开发基于脂质纳米颗粒递送系统的基因治疗创新工艺解决方案,以推动基因编辑技术在遗传性疾病治疗领域的突破。这也是丹纳赫第一次携手中国生物技术企业开展Danaher Beacon合作。基因遗传性疾病是由基因突变引起,包括镰刀型贫血症、囊性纤维化、杜氏肌营养不良等数千种疾病。绝大部分基因遗传性疾病...
Source Link7月14日,全球科学与技术的创新者丹纳赫在沪宣布其旗下运营公司Cytiva思拓凡与正序生物开展战略合作,共同开发基于脂质纳米颗粒递送系统的基因治疗创新工艺解决方案,以推动基因编辑技术在遗传性疾病治疗领域的突破。这也是丹纳赫第一次携手中国生物技术企业开展Danaher Beacon合作。基因遗传性疾病是由基因突变引起,包括镰刀型贫血症、囊性纤维化、杜氏肌营养不良等数千种疾病。绝大部分基因遗传性疾病...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.